دورية أكاديمية
FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma.
| العنوان: | FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. |
|---|---|
| المؤلفون: | Tanuma J; Department of Oral Pathology, Field of Oncology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8544, Japan. tanuma@dent.kagoshima-u.ac.jp, Izumo T, Hirano M, Oyazato Y, Hori F, Umemura E, Shisa H, Hiai H, Kitano M |
| المصدر: | Oncology reports [Oncol Rep] 2010 Mar; Vol. 23 (3), pp. 739-44. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print Cited Medium: Internet ISSN: 1791-2431 (Electronic) Linking ISSN: 1021335X NLM ISO Abbreviation: Oncol Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2003->: Athens : D.A. Spandidos Original Publication: [Athens, Greece] : National Hellenic Research Foundation, 1994- |
| مواضيع طبية MeSH: | Genes, p53* , Mutation* , Polymorphism, Genetic*, Carcinoma, Squamous Cell/*genetics , Mouth Neoplasms/*genetics , Receptor, Fibroblast Growth Factor, Type 4/*genetics, Adult ; Aged ; Aged, 80 and over ; Carcinoma, Squamous Cell/mortality ; Female ; Genotype ; Humans ; Male ; Middle Aged ; Mouth Neoplasms/mortality ; Prognosis |
| مستخلص: | The genotype of the fibroblast growth factor receptor 4 (FGFR4) gene and TP53 mutation have been reported as prognostic factors for cancers of the head and neck, bladder, breast and colon. To determine whether they are applicable for oral squamous cell carcinoma (OSCC), we investigated these two genes in OSCC samples from 150 patients who had undergone radical surgery and in 100 cancer-free individuals. In OSCC, the FGFR4 Gly388Arg polymorphism and the presence or absence of mutation in TP53 did not show a significant association with the clinicopathological features of the tumors at surgery. However, the FGFR4 Arg388 allele, as well as mutations in TP53, was found to be closely associated with poor prognosis. Moreover, these two parameters synergistically affected the survival of OSCC patients. During 60 months of observation after radical surgery, a majority of patients with homozygous Arg388 FGFR4 plus mutated TP53 died of cancer, whereas >90% patients carrying homozygous Gly388 FGFR4 plus wild-type TP53 survived. Therefore, the FGFR4 Gly388Arg polymorphism and TP53 mutations, as well as their combinations, are excellent predictors of the prognosis for OSCC patients. |
| المشرفين على المادة: | EC 2.7.10.1 (FGFR4 protein, human) EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 4) |
| تواريخ الأحداث: | Date Created: 20100204 Date Completed: 20100429 Latest Revision: 20120605 |
| رمز التحديث: | 20231215 |
| PMID: | 20127014 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1791-2431 |
|---|